[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"scar-formation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:scar-formation":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100622739","phase-4-the-effectiveness-of-topical-silicone-application-combined-with-photoprotection-in-the-development-of-scarring-following-blepharoplasty-100622739",false,"NCT07387536","The Effectiveness of Topical Silicone Application Combined With Photoprotection in the Development of Scarring Following Blepharoplasty","ETSACPDSFP","Inclusion Criteria:\n\n* The study participants are individuals aged 18 years and older, encompassing both male and female subjects. These participants are undergoing blepharoplasty and have provided their written informed consent to partake in the research.\n\nExclusion Criteria:\n\n* Individuals with a history of previous surgical procedures on the eyelids, apart from the current blepharoplasty. . Those who have previously undergone intralesional modulation are also considered. Individuals with a known allergy to any components of the product under investigation. The presence of local skin infections in the treatment area. Suspicious skin lesions suggestive of malignancy in the eyelid region. Pregnancy or breastfeeding during the study. - Research subjects who, after being included in the study, do not complete the scheduled clinical follow-up. Research subjects who discontinue the use of the topical treatment before the end of the established period. Voluntary withdrawal of informed consent at any stage of the study. Later detection of exclusion criteria that were not identified during the initial evaluation.","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","Assess the efficacy of utilizing topical silicone with photoprotection (Improscar Stick® 50) on the quality of healing following upper blepharoplasty, employing the Vancouver and POSAS scales (both patient and observer) over a minimum follow-up period of three months.",[26],"Scar Formation",[28,29,30],"Upper Blepharoplasty Approach","Post-operative Scar","Vancouver Scar Scale","RECRUITING","2026-01-28",{"date":34,"type":35},"2026-02-04","ACTUAL",{"date":37,"type":35},"2025-10-01",{"date":39,"type":20},"2026-05-31",{"name":41,"class":42},"Instituto de Oftalmología Fundación Conde de Valenciana","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":43},"100603374","phase-4-study-to-use-oral-losartan-to-decrease-the-risk-of-postoperative-scarring-following-acl-reconstruction-100603374","NCT07135687","Study to Use Oral Losartan to Decrease the Risk of Postoperative Scarring Following (ACL) Reconstruction","Oral Losartan to Decrease the Risk of Postoperative Arthrofibrosis Following Primary and Revision Anterior Cruciate Ligament Reconstruction","Inclusion Criteria:\n\n* Must be undergoing a primary ACLR with or without the following:\n* Chondroplasty\n* Synovectomy\n* Loose body removal\n* Removal of hardware\n* Meniscal surgery (excluding meniscal allograft transplantation\u002FMAT)\n* Lateral extra-articular tenodesis\n* Must have skeletal maturity in the distal femur and proximal tibial physes\n* Must be age 18 years or older at time of enrollment\n\nExclusion Criteria:\n\n* \\\u003C18 years at time of enrollment\n* No diagnosis of ACL tear\n* ACL repairs\n* Revision ACL reconstructions\n* Open distal femur or proximal tibia physes\n* Major concomitant procedures (such as osteotomy, MAT, or cartilage restoration surgery)\n* History of prior proximal or distal femur fracture (including those receiving nonoperative treatment)\n* History of prior ipsilateral femur or tibia osteomyelitis\n* Medical history\n* History of hypotensive disease, including postural orthostatic hypotension syndrome (POTS), autonomic dysreflexia, or Shy-Drager syndrome (aka multiple system atrophy), baseline hypotension \\\u003C90 systolic or \\\u003C60 diastolic mmHg.\n* History of significant hepatic disease (liver transplantation, cirrhosis of any cause, or any liver disease with Child-Pugh classification B or C) due to hepatic metabolism of ARBs.\n* Chronic kidney disease\n* Rheumatologic disorders on immunologic medications\n* Current medications including diuretics (i.e. furosemide), lithium, and spironolactone\n* Current hypertension with prescription of an ARB or ACE-I\n* Allergy to losartan\n* Current pregnancy or breastfeeding",{"count":52,"type":20},144,[23],"The purpose of this study to investigate the effect of using losartan (a blood pressure lowering drug with anti-scarring properties) on preventing primary postoperative arthrofibrosis (formation of abnormal scar tissue) in the knees in participants undergoing anterior cruciate ligament (ACL) repair surgery of their knee.",[56,57,26],"ACL Injury","ACL Reconstruction",[59,60,61],"ACL","Postoperative Arthrofibrosis","Losartan","NOT_YET_RECRUITING","2025-12-09",{"date":65,"type":35},"2025-12-15",{"date":67,"type":20},"2026-08",{"date":69,"type":20},"2028-12",{"name":71,"class":42},"Rush University Medical Center",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":4},"100588657","phase-1-effect-of-yap1-inhibition-in-surgical-wounds-100588657","NCT06944249","Effect of YAP1-inhibition in Surgical Wounds.","The Role of YAP1 in Fibrosis Explored Through Its Local Inhibition With Verteporfin in Surgical Wounds: A Randomized Controlled, Prospective, Evaluator-blinded Proof-of-concept Study.","Inclusion Criteria:\n\n* Willing and able to provide informed consent as documented by signature\n* Age is \\>\u002F= 18 years and \\\u003C 56 years (differently said: starting from the 18th birthday to completion of their 55 years)\n* Indication for a safety margin excision (5 mm laterally) due to melanoma in situ or severe dysplastic nevi previously completely excised\n* Length of initial scar from 15 mm to 50 mm\n* The initial lesion was excised on the back (to ensure that all patients undergo their safety margin excision within the internationally accepted timeframe, we will also accept patients requiring the procedure at another anatomical site if a particular batch cannot be filled within 4 weeks of its first patient's enrollment)\n\nExclusion Criteria:\n\n* Clinical adenopathy (cervical, axillar, inguinal) defined as a lymph node of more than 1 cm diameter\n* Melanoma in situ of lentigo maligna or acral lentiginous type\n* Head and neck location\n* Diameter of initial lesion above or equal to 3 cm\n* Known and documented hypersensitivity to Verteporfin or to any of its excipients: lactose monohydrate, egg phosphatidylglycerol (to simplify we will exclude patients with known and documented allergy to egg protein), dimyristoyl phosphatidylcholine, ascorbyl palmitate, butylated hydroxytoluene (E321)\n* Porphyria\n* Moderate hepatic dysfunction referred to as any of the following: AST \\>1.2x upper normal range, ALT \\>1.2x upper normal range, decreased albumin level, prolongation of PT\n* Biliary obstruction referred to as any of the following: ALP \\>1.2x upper normal range, GGT \\>1.2x upper normal range, anormal bilirubin level\n* Pregnancy referred to as: positive beta-hCG blood test\n* Breast-feeding\n* Planned pregnancy in the next 6 months\n* History of either one of the following: keloids, scleroderma, morphea, lupus erythematosus, nephrogenic systemic fibrosis, graft-versus-host disease, lichen sclerosus, eosinophilic fasciitis, Ehlers-Danlos syndrome, cutis laxa, Marfan syndrome, or pseudoxanthoma elasticum","55 Years",{"count":81,"type":20},24,[83,84],"PHASE1","PHASE2","When we get injured, our body naturally tries to heal. In adults, this healing often leads to scars - thick, stiff tissue known as fibrotic tissue. Unlike normal tissue, fibrotic tissue doesn't function properly and can cause serious health problems, depending on the affected organ. Once it forms, fibrosis is usually permanent.\n\nA good example of the fibrosis process is the healing of our skin: after a cut or surgery, the resulting scar is a type of fibrosis. Special cells called fibroblasts are key players in this process.\n\nOur study looks at a drug called verteporfin, which is already approved both in Europe and the U.S. Previous research on mice and human cells suggests it can reduce or even prevent fibrosis.\n\nWe are now testing, clinically, histologically and by scRNA-seq, whether injecting verteporfin into the skin during wound healing, specifically after surgical procedures, can prevent thick, rigid scars from forming. Since the skin is easy to observe and sample, it offers a great model for studying this.\n\nWill verteporfin have an impact on how surgical wounds heal? That's what we aim to find out.",[26],[88,89,90,91,92],"YAP1","Verteporfin","Scar","Fibrosis","Wound healing","2025-04-17",{"date":95,"type":35},"2025-04-25",{"date":97,"type":20},"2025-05-08",{"date":99,"type":20},"2026-07-31",{"name":101,"class":42},"Jöri Pünchera"]